Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 70

Sort by

Sort Order Select

Journal Articles

A Phase Ib/II Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML

Iman Aboudalle, MD, Marina Y Konopleva, MD PhD, Tapan M. Kadia, MD, Kiran Naqvi, MDMPH, Kenneth Vaughan, RN, Mehmet Kurt, RN, Antonio Cavazos, Sherry A. Pierce, BSN, BA, Koichi Takahashi, MD, Lucia Masarova, MD, Musa E. Yilmaz, MD, Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Steven M. Kornblau, MD, Farhad Ravandi, MD, Jorge Cortes, MD, Hagop M. Kantarjian, MD, Courtney D. DiNardo, MD MSc

Blood (2019) 134 (Supplement_1): 176.

https://doi.org/10.1182/blood-2019-121780

Published: 2019

Journal Articles

Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome

Kelly S. Chien, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MDMPH, Naval G. Daver, MD, Jorge E. Cortes, MD, Courtney D. DiNardo, MDMSc, Elias Jabbour, MD, Michael Andreeff, MD PhD, Yesid Alvarado, MD, Prithviraj Bose, MD, Nitin Jain, MD, Kimberly Sheppard, BSN, RN, Cheri Klingner-Winton, Sherry A. Pierce, BSN, BA, Xiao Qin Dong, Kelly Soltysiak, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 4240.

https://doi.org/10.1182/blood-2019-129598

Published: 2019

Journal Articles

Haploidentical Stem Cell Transplantation in Advanced Stage Mycosis Fungoides and Sézary Syndrome: A Report of Four Consecutive Cases from a Single Center

Francesco Onida, MD, Giorgia Saporiti, MD, Viviana Beatrice Valli, MD, Silvia Alberti Violetti, MD, Federica Irene Grifoni, MD, Maria Cecilia Goldaniga, MD, Mariarita Sciumè, MD, Luca Baldini, MD PhD, Emilio Berti, MD

Blood (2019) 134 (Supplement_1): 5744.

https://doi.org/10.1182/blood-2019-131501

Published: 2019

Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2019) 134 (Supplement_1): 34.

https://doi.org/10.1182/blood-2019-131847

Published: 2019

Journal Articles

Ixazomib Maintenance to Prevent Alloreactivity and Provide Anti-Malignancy Effects Following Nonmyeloablative T-Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Scott R. Solomon, MD, Melhem Solh, MD, Stacey Brown, CCRP, Katelin C Jackson, Xu Zhang, PhD, Lawrence E Morris, MD, H. Kent Holland, MD, Asad Bashey, MD PhD

Blood (2019) 134 (Supplement_1): 1998.

https://doi.org/10.1182/blood-2019-124354

Published: 2019

Journal Articles

Low-Dose Azacitidine, Pioglitazone and All-Trans Retinoic Acid Versus Standard-Dose Azacitidine in Patients ≥ 60 Years with Acute Myeloid Leukemia Refractory to Standard Induction Chemotherapy (AMLSG 26-16/AML-ViVA): Results of the Safety Run-in Phase I

Daniel Heudobler, Sebastian Klobuch, MD, Florian Lüke, MD, Joachim Hahn, MD, Matthias Grube, MD, Stephan Kremers, MD, Thomas Südhoff, MD, Jörg Westermann, MD, Marie-Luise Huetter-Kroenke, MD, Peter Paschka, MD, Gauthier Bouche, Hartmut Döhner, MD, Wolfgang Herr, MD, Simone Thomas, MD, Albrecht Reichle, MD

Blood (2019) 134 (Supplement_1): 1382.

https://doi.org/10.1182/blood-2019-129977

Published: 2019

Journal Articles

Patterns of Infection and Mortality Associated with Intensive AML Induction Therapy: 10 Year Experience from a Tertiary Cancer Centre in India

Hemanth Kumar, MBBS, MD, Nikita Mehra, MD DM, Prasanth Ganesan, MD DM, Venkatraman Radhakrishnan, MD DM, Manikandan Dhanushkodi, MD DM, Jayachandran P K, MD DM, Trivadi S Ganesan, MD DM, S Krupa Shankar, MD DM, Tenali Gnana Sagar, MD DM, Krishnarathinam Kannan, MD DM

Blood (2018) 132 (Supplement 1): 4008.

https://doi.org/10.1182/blood-2018-99-119919

Published: 2018

Journal Articles

Impact of Ruxolitinib in Myelofibrosis Allogeneic Stem Cell Transplant Outcome---a Pilot Study

Joyson Poulose, MD, Jozef Malysz, MD, David F Claxton, MD, W. Christopher Ehmann, Shin Mineishi, Witold B. Rybka, Raymond J. Hohl, Jeffrey J Pu, MDPhD

Blood (2017) 130 (Supplement 1): 5543.

https://doi.org/10.1182/blood.V130.Suppl_1.5543.5543

Published: 2017

Journal Articles

Outcome of BCR-ABL/Philadelphia Positive Acute Lymphoblastic Leukemia: A Single Centre Experience from Developing Country

Narendra Agrawal, MD DM, Priyanka Verma, MD, Neha Yadav, BDS , MBA, Rayaz Ahmed, MDDM, Mukul Aggarwal, DM, Pragya Bhandari, MD, Niharika Bhatia, MSc, Jyotsna Kapoor, MSc, Dinesh Bhurani, MD DM, FRCPA

Blood (2017) 130 (Supplement 1): 5006.

https://doi.org/10.1182/blood.V130.Suppl_1.5006.5006

Published: 2017

Journal Articles

Increased Incidence of Autoimmune and Infectious Diseases Among a Large Group of Diffuse Large B-Cell Lymphoma (DLBCL) Survivors: A Population-Based Study

Tanaya Shree, MD PhD, Qian Li, MS, Sally L. Glaser, PhD, Holden T. Maecker, PhD, Robert W. Haile, PhD MPH, Ronald Levy, MD, Theresa H.M. Keegan, PhD MS

Blood (2017) 130 (Supplement 1): 198.

https://doi.org/10.1182/blood.V130.Suppl_1.198.198

Published: 2017

Journal Articles

Sequential Therapy for Patients with Primary Refractory AML — a Retrospective Analysis of the German and Israeli Experience

Ron Ram, MD, Christof Scheid, MD, Odelia Amit, BSc, Jens Markus Chemnitz ‎, MD, Yakir Moshe, MD, Michael Hallek, MD, Dominik Wolf‎, Irit Avivi, MD, Udo Holtick, MD PhD

Blood (2017) 130 (Supplement 1): 4579.

https://doi.org/10.1182/blood.V130.Suppl_1.4579.4579

Published: 2017

Journal Articles

Initial Results of a Phase Ib Study of Ibrutinib in Combination with Obinutuzumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Matthew S. Davids, MD, Haesook T Kim, PhD, Alexandra Savell, BS, Carlos Santiago-Medero, Karen Francoeur, RN, Jeremy S. Abramson, MD MMSc, Eric D. Jacobsen, MD, Ann S LaCasce, MD MSc, David C. Fisher, MD PhD, Jennifer R. Brown, MD PhD

Blood (2017) 130 (Supplement 1): 4317.

https://doi.org/10.1182/blood.V130.Suppl_1.4317.4317

Published: 2017

Journal Articles

A Pilot Study of CX-01 with Azacitidine for Treatment of Hypomethylating Agent-Refractory AML and MDS

Eric Huselton, MD, Amanda F. Cashen, MD, John F DiPersio, MD PhD, Meagan Jacoby, MD PhD, Iskra Pusic, MD, Rizwan Romee, MD, Geoffrey L. Uy, MD, Peter Westervelt, MDPhD

Blood (2017) 130 (Supplement 1): 5067.

https://doi.org/10.1182/blood.V130.Suppl_1.5067.5067

Published: 2017

Journal Articles

Interim Results of a Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia

Alison R. Walker, MD MPH, Bhavana Bhatnagar, DO, A. Mario Q. Marcondes, MD, Julie DiPaolo, PhD, Sumithra Vasu, MBBS, Alice S. Mims, MD MSCR, Rebecca B. Klisovic, MD, Katherine J. Walsh, MD, Renee Canning, RN, Gregory K. Behbehani, MD PhD, Ramiro Garzon, MD, James S. Blachly, MD, Amy J. Johnson, PhD, Esteban Abella-Dominicis, John C. Byrd, MD, William Blum, MD

Blood (2016) 128 (22): 2831.

https://doi.org/10.1182/blood.V128.22.2831.2831

Published: 2016

Journal Articles

Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation

Daniel W. Lee, III, MD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Nirali N Shah, MD, Cindy Delbrook, RN, Bonnie Yates, RN, PNP, Hua Zhang, PhD, Ling Zhang, PhD, James N. Kochenderfer, MD, Steven A. Rosenberg, MD PhD, Terry J Fry, MD, David Stroncek, MD, Crystal L. Mackall, MD

Blood (2016) 128 (22): 218.

https://doi.org/10.1182/blood.V128.22.218.218

Published: 2016

Journal Articles

Decitabine (DAC) in Combination with Donor Lymphocyte Infusions (DLIs) Can Induce Remissions of Overt Aml Relapses after Allogeneic Transplantation

Sebastian Sommer, MD, Rainer Claus, MD, Hartmut Bertz, MD, Ralph Wäsch, MD, Reinhard Marks, MD, Robert Zeiser, MD, Ljudmila Bogatyrova, Jürgen Finke, MD, Michael Lübbert, MD

Blood (2016) 128 (22): 2247.

https://doi.org/10.1182/blood.V128.22.2247.2247

Published: 2016

Journal Articles

In-Hospital Outcomes of Neutropenic Fever: A Study Using the National Inpatient Sample, Years 2009-2013

Urshila Durani, MD MPH, Ronald S. Go, MD

Blood (2016) 128 (22): 4762.

https://doi.org/10.1182/blood.V128.22.4762.4762

Published: 2016

Journal Articles

Neutrophil Recruitment Is Regulated By Adamts-13 in a Murine Model of Invasive Aspergillosis

Astrid Hasibeder, Steve Prüfer, Katharina Ebner, Sebastian Reuter, Pamela Stein, Inge Scharrer, Fumiaki Banno, Michael Stassen, Hansjörg Schild, Kerstin Jurk, Markus Bosmann, Markus P. Radsak

Blood (2015) 126 (23): 1010.

https://doi.org/10.1182/blood.V126.23.1010.1010

Published: 2015

Journal Articles

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Leukemias

Blood (2015) 126 (23): 1361.

https://doi.org/10.1182/blood.V126.23.1361.1361

Published: 2015

Journal Articles

The Vascular Disrupting Agent OXi4503 in Relapsed and Refractory AML and MDS

Shannon Somer Stockton, BA, Leslie Pettiford, RN, MS, CCRC, Christina Cline, RN, BSN, David Chaplin, PhD, Jack W Hsu, John R. Wingard, MD, Christopher R. Cogle, MD

Blood (2015) 126 (23): 4936.

https://doi.org/10.1182/blood.V126.23.4936.4936

Published: 2015

NARROW

A Phase Ib/II Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML

Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome

Haploidentical Stem Cell Transplantation in Advanced Stage Mycosis Fungoides and Sézary Syndrome: A Report of Four Consecutive Cases from a Single Center

Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)

Ixazomib Maintenance to Prevent Alloreactivity and Provide Anti-Malignancy Effects Following Nonmyeloablative T-Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Low-Dose Azacitidine, Pioglitazone and All-Trans Retinoic Acid Versus Standard-Dose Azacitidine in Patients ≥ 60 Years with Acute Myeloid Leukemia Refractory to Standard Induction Chemotherapy (AMLSG 26-16/AML-ViVA): Results of the Safety Run-in Phase I

Patterns of Infection and Mortality Associated with Intensive AML Induction Therapy: 10 Year Experience from a Tertiary Cancer Centre in India

Impact of Ruxolitinib in Myelofibrosis Allogeneic Stem Cell Transplant Outcome---a Pilot Study

Outcome of BCR-ABL/Philadelphia Positive Acute Lymphoblastic Leukemia: A Single Centre Experience from Developing Country

Increased Incidence of Autoimmune and Infectious Diseases Among a Large Group of Diffuse Large B-Cell Lymphoma (DLBCL) Survivors: A Population-Based Study

Sequential Therapy for Patients with Primary Refractory AML — a Retrospective Analysis of the German and Israeli Experience

Initial Results of a Phase Ib Study of Ibrutinib in Combination with Obinutuzumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

A Pilot Study of CX-01 with Azacitidine for Treatment of Hypomethylating Agent-Refractory AML and MDS

Interim Results of a Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia

Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation

Decitabine (DAC) in Combination with Donor Lymphocyte Infusions (DLIs) Can Induce Remissions of Overt Aml Relapses after Allogeneic Transplantation

In-Hospital Outcomes of Neutropenic Fever: A Study Using the National Inpatient Sample, Years 2009-2013

Neutrophil Recruitment Is Regulated By Adamts-13 in a Murine Model of Invasive Aspergillosis

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Leukemias

The Vascular Disrupting Agent OXi4503 in Relapsed and Refractory AML and MDS

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only